Surgery Partners vs Tenet Healthcare
SGRY and THC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SGRY and THC compare
Tenet Healthcare is the larger company, worth 7.2 times as much as Surgery Partners ($22.0B against $3.0B).
Tenet Healthcare grew revenue faster over the last twelve months (6.2% versus 4.0% for Surgery Partners).
Tenet Healthcare scores higher on the StockData Score (13 against 6 for Surgery Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SGRY | THC |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | $22.0B |
| Share price | $23.21 | $273.25 |
| Change, 1 year | 2.0% | 30.7% |
| Change, 5 years | −53.7% | 262% |
| Beta (5Y) | 1.64 | 1.15 |
| Employees | 16K | 100K |
| StockData Score | ||
| Total score | 6 | 13 (better) |
| Valuation score | 2 | 5 (better) |
| Growth score | 0 | 3 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 7.9× |
| P/S | 0.9× (better) | 1.0× |
| P/B | 1.8× (better) | 4.0× |
| EV/EBITDA | 14.3× | 5.5× (better) |
| P/FCF | 16.2× | 6.6× (better) |
| PEG | – | 0.13 |
| FCF yield | 6.2% | 15.1% (better) |
| Fair value | $21.97 | $449.89 |
| Margin of safety | −5.7% | 39.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 4.0% | 6.2% (better) |
| Revenue growth, 5Y average | 12.2% (better) | 3.9% |
| EPS growth (TTM) | – | 136% |
| EPS growth, 5Y average | – | 32.8% |
| Profitability | ||
| Operating margin | 11.4% | 24.4% (better) |
| Net margin | −2.6% | – |
| FCF margin | 5.6% | 15.0% (better) |
| Return on equity | −5.2% | – |
| Return on invested capital | 5.9% | 28.2% (better) |
| Financial health | ||
| Debt / equity | 2.25 (better) | 2.43 |
| Net debt / EBITDA | 6.30 | 1.68 (better) |
| Interest coverage | – | 6.6× |
| Current ratio | 1.95 (better) | 1.58 |
| Altman Z-score | 0.87 | 2.29 (better) |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Buyback yield | – | 8.2% |
| Shareholder yield | 0.00% | 8.2% (better) |
| Ownership | ||
| Held by institutions | 121% | 100% |
| Held by insiders | 85.9% | 0.96% |
| Insider net buying, 12 months | −$979K (better) | −$71.2M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 77.9% | 2.3% |
Go deeper
- SGRY stock overview
- SGRY income statement
- SGRY valuation and score
- THC stock overview
- THC income statement
- THC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.